{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:34:42Z","timestamp":1786736082155,"version":"build-2736575974"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Endocr Metab"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijem.ijem_678_18","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T02:28:53Z","timestamp":1558405733000},"page":"269","source":"Crossref","is-referenced-by-count":9,"title":["Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction"],"prefix":"10.4103","volume":"23","author":[{"given":"ThomasV","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remya","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KripaElizabeth","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2230-8210.258693-1","unstructured":"US Food and Drug Administration. FDA drug safety communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm270199.htm. [Last accessed on 2012 Feb 09]."},{"key":"key-10.4103\/2230-8210.258693-2","doi-asserted-by":"crossref","unstructured":"Cetani F, Saponaro F, Marcocci C. Non-surgical management of primary hyperparathyroidism, Best Practice & Research Clinical Endocrinology & Metabolism 2018;32:821-35. Available from: https:\/\/doi.org\/10.1016\/j.beem. 2018.09.006.","DOI":"10.1016\/j.beem.2018.09.006"},{"key":"key-10.4103\/2230-8210.258693-3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/11203300-000000000-00000","article-title":"Denosumab: A review of its use in the treatment of postmenopausal osteoporosis","author":"Moen","year":"2011","journal-title":"Drugs Aging"},{"key":"key-10.4103\/2230-8210.258693-4","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.clml.2014.07.005","article-title":"Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction","author":"Cicci","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key-10.4103\/2230-8210.258693-5","first-page":"41","article-title":"Denosumab as a bridge to surgery in patients with primary hyperparathyroidism, severe hypercalcemia and renal impairment","author":"Pugliese","year":"2016","journal-title":"Curr Trends Endocrinol"},{"key":"key-10.4103\/2230-8210.258693-6","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.2217\/fon.15.232","article-title":"Denosumab: A new agent in the management of hypercalcemia of malignancy","author":"Thosani","year":"2015","journal-title":"Future Oncol"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:37:05Z","timestamp":1786732625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.IJEM_678_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"alternative-id":["258693"],"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_678_18","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}